Javier Munoz, MD, Hematology, Phoenix, AZ

JavierMunozMDMS, FACP

Hematology Phoenix, AZ

Hematologic Oncology

Director, Lymphoma Program at Mayo Clinic.

Dr. Munoz is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Munoz's full profile

Already have an account?

  • Office

    5881 E. Mayo Boulevard
    Mayo Clinic Building Office CB 3-337
    Phoenix, AZ 85054
    Phone(480) 342-4800
    Fax(480) 301-4675
  • Is this information wrong?

Summary

  • Dr. Munoz specializes in treating lymphomas and he is the Director of the Lymphoma Program at Mayo Clinic in Arizona. He is triple board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Munoz also completed a Master of Science in patient-based research and an Investigational Cancer Therapeutics fellowship at the University of Texas MD Anderson Cancer Center in Houston before relocating to Arizona. He is principal investigator in multiple cutting-edge lymphoma trials including immunotherapy and Chimeric Antigen Receptors (CAR) T-cells. Dr. Munoz has published in major internationally renowned journals including the New England Journal of Medicine, the American Journal of Hematology, Nature Reviews and JAMA. Dr. Munoz's personal goal is drug development of non-chemotherapy targeted agents via novel clinical trials to serve patients suffering with lymphoma.
  • ASH Choosing Wisely® Champions - Javier Munoz, MD

    Javier Munoz, MD, of Banner MD Anderson Cancer Center in Gilbert, Arizona, was selected as one of the three inaugural ASH Choosing Wisely Champions

    Movimiento en la búsqueda de una alternativa contra el cáncer

    Investigaciones buscan una alternativa para tratar el cáncer, que incluso podría erradicarlo. Primer Impacto: Encuentra las noticias y reportajes más impactante

    Why Watch and Wait Is Necessary

    Why is the watch-and-wait period necessary for many people with chronic lymphocytic leukemia (CLL)? Dr. Javier Munoz, from Banner MD Anderson Cancer Center, exp

Education & Training

  • Henry Ford Hospital - Wayne State University
    Henry Ford Hospital - Wayne State UniversityFellowship
  • Henry Ford Hospital - Wayne State University
    Henry Ford Hospital - Wayne State UniversityResidency
  • Cayetano Heredia University
    Cayetano Heredia UniversityMedicalSchool
  • University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer CenterFellowship

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2012 - 2021
  • TX State Medical License
    TX State Medical License 2011 - 2017
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • ASH Hematology Opportunities for the Next-generation of Research Scientists HONORS Award (Mentor) American Society of Hematology, 2019
  • Health Volunteers Overseas (HVO) American Society of Hematology, 2018
  • ASCO Virtual Mentoring Program American Society of Clinical Oncology, 2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...
    Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
    Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
    Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Reduction of Post-Treatment Scanning Using EMR Alerts 
    ASH San Diego 2016 - The ASH Choosing Wisely® Campaign: 2016 ASH Choosing Wisely Champions - 12/5/2016

Press Mentions

  • ASCO Mentoring Helps Early-Career Oncologists
  • Difficult-to-Treat Mantle Cell Lymphoma Responds to CAR T-Cell Therapy
  • Advances in diagnosis and treatment of MCL
  • Join now to see all

Other Languages

  • Spanish